TY - JOUR
T1 - Somatostatin receptor localization of pancreatic endocrine tumors
AU - Corleto, V. D.
AU - Scopinaro, F.
AU - Angeletti, S.
AU - Materia, A.
AU - Basso, N.
AU - Polettini, E.
AU - Annibale, B.
AU - Schillaci, O.
AU - D'Ambra, G.
AU - Marignani, M.
AU - Gualdi, G.
AU - Bordi, C.
AU - Passaro, E. J.
AU - Delle Fave, G.
PY - 1996
Y1 - 1996
N2 - Gastroenteropancreatic endocrine tumors are difficult to localize. At the same time the tumor is localized, though, there is an opportunity for care or to remove tumor tissue. In this study we have prospectively examined the ability of 111In-octreotide scintigraphy, magnetic resonance imaging (MRI), and computed tomography (CT) to localize tumor lesions in 24 patients with a biochemical or histologic diagnosis of neuroendocrine tumor. In eight patients a surgical assessment of the imaging results was prospectively performed. Planar and abdominal single-photon emission tomography (SPET) images acquired 4 and 24 hours after 180 to 220 MBq of 111In-octreotide injection were evaluated and compared with conventional imaging techniques. SPET scintigraphy visualized more presumed tumor lesions (n = 39) than conventional imaging studies (MRI, n = 25; CT, n = 13); 23 of 24 patients had positive octreotide scintigraphy, 17 of 24 had positive MRI-scans, and 12 of 24 patients had positive CT scans. It was concluded that 111In-octreotide scintigraphy combined with conventional imaging improves the preoperative localization of presumably tumorous lesions in patients with gastroenterohepatic endocrine tumors.
AB - Gastroenteropancreatic endocrine tumors are difficult to localize. At the same time the tumor is localized, though, there is an opportunity for care or to remove tumor tissue. In this study we have prospectively examined the ability of 111In-octreotide scintigraphy, magnetic resonance imaging (MRI), and computed tomography (CT) to localize tumor lesions in 24 patients with a biochemical or histologic diagnosis of neuroendocrine tumor. In eight patients a surgical assessment of the imaging results was prospectively performed. Planar and abdominal single-photon emission tomography (SPET) images acquired 4 and 24 hours after 180 to 220 MBq of 111In-octreotide injection were evaluated and compared with conventional imaging techniques. SPET scintigraphy visualized more presumed tumor lesions (n = 39) than conventional imaging studies (MRI, n = 25; CT, n = 13); 23 of 24 patients had positive octreotide scintigraphy, 17 of 24 had positive MRI-scans, and 12 of 24 patients had positive CT scans. It was concluded that 111In-octreotide scintigraphy combined with conventional imaging improves the preoperative localization of presumably tumorous lesions in patients with gastroenterohepatic endocrine tumors.
UR - http://www.scopus.com/inward/record.url?scp=13344282053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13344282053&partnerID=8YFLogxK
U2 - 10.1007/s002689900038
DO - 10.1007/s002689900038
M3 - Article
C2 - 8661825
AN - SCOPUS:13344282053
VL - 20
SP - 241
EP - 244
JO - World Journal of Surgery
JF - World Journal of Surgery
SN - 0364-2313
IS - 2
ER -